The ANCA-associated vasculitis (AAV) has an exceptionally high morbidity and mortality especially in patients with diffuse alveolar hemorrhage (DAH). Data on DAH in elderly AAV patients is still very limited. To investigate the impact of DAH on patient survival, relapse-free survival, death from infectious complications, and the incidence of pneumonia in one of the most vulnerable but often underrepresented AAV subpopulation-elderly patients. We included 139 AAV patients in this retrospective cohort study and performed a 5-year follow-up. AAV patients were divided into patients ≤ 65 and > 65 years ("elderly"). Elderly AAV patients were further subdivided into patients with and without DAH. Relapse-free survival was comparable (P = 0.49) whereas overall patient survival (P = 0.01) was significantly lower in patients > 65 as compared to ≤ 65 years. Death due to infectious complications occurred more frequently in the elderly cohort (log-rank P = 0.02). Especially the incidence of pneumonia (including opportunistic pathogens) was considerably higher in elderly AAV patients (log-rank P = 0.001). Overall survival in elderly patients was significantly lower in patients with as compared to patients without DAH [8/18 (44%) versus 9/52 (17%) deaths (P = 0.02)] while relapse-free survival was again comparable (P = 0.87) between both groups. Notably, 6 out of 8 fatal outcomes in elderly DAH patients were associated with severe infections. In multivariate analyses, age and glucocorticoid (GC) dose at 3 months were the only predictors of death from infectious complications, whereas this could not be independently demonstrated for DAH. Life-threatening infections with (opportunistic) pneumonia are common in elderly AAV patients with DAH during the first 12 months and higher GC dose was an independent predictor of death from infectious complications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876205 | PMC |
http://dx.doi.org/10.1007/s00296-025-05812-8 | DOI Listing |
Rheumatology (Oxford)
March 2025
Department of Medicine, McMaster University, Hamilton, ON, Canada.
ANCA-associated vasculitis (AAV) is a heterogeneous autoimmune disease marked by varying organ involvement and outcomes. Plasma exchange, a method of removing native plasma and replacing it with crystalloid, albumin or donor plasma, can deplete autoantibodies and may help control autoimmune diseases rapidly. In AAV, several randomized controlled trials have been performed but, individually, had mixed results.
View Article and Find Full Text PDFRheumatology (Oxford)
March 2025
Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
This session presented emerging realworld evidence on novel glucocorticoid (GC) sparing therapies for ANCA-associated vasculitis (AAV). It covered the first-in-class oral C5a receptor antagonist avacopan for severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and antiinterleukin-5 therapies in the management of eosinophilic granulomatosis with polyangiitis (EGPA). Avacopan was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of AAV in 2021, following the phase 3 ADVOCAT E trial comparing oral avacopan to an oral GC taper for GPA and MPA.
View Article and Find Full Text PDFRheumatology (Oxford)
March 2025
Vasculitis Expertise Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
In this plenary session of the Vasculitis Workshop 2024, pioneering translational research on autoimmune vasculitis, particularly ANCA-associated vasculitis (AAV), was presented, highlighting advancements in our understanding of disease mechanisms and promising therapeutic prospects. Advances in elucidating molecular pathways, such as IL-17 and IFN-I, pave the way for specific treatments. Preclinical studies have revealed the gut microbiome's role in the pathogenesis of MPO-AAV and demonstrate the therapeutic potential of dietary interventions.
View Article and Find Full Text PDFRheumatology (Oxford)
March 2025
Vasculitis Unit of Vienna, Vienna, Austria.
The plenary session on clinically relevant outcomes in systemic vasculitis emphasized the significance of monitoring creatinine, haematuria and proteinuria for predicting renal outcomes, recovery of kidney function in severe ANCA glomerulonephritis and outcomes post-kidney transplantation in anti-glomerular basement membrane disease. These findings have the potential to enhance clinical practice by refining prognostication and treatment strategies. Future research gaps include exploring the predictive role of proteinuria and understanding the impact of different clinical phenotypes on disease outcomes in Takayasu arteritis.
View Article and Find Full Text PDFRheumatology (Oxford)
March 2025
Rheumatology Department, Health New Zealand, Auckland, New Zealand.
The session on 'Diagnosis and Classification of Vasculitis' featured six oral presentations covering various aspects of vasculitis diagnosis and classification. The application of the Ankara criteria for IgA vasculitis in adults was evaluated, finding that while the criteria showed good sensitivity, their specificity was insufficient, suggesting the need for refinement. A clustering approach to classifying ANCA-associated vasculitis (AAV) identified five distinct clusters, which improved prediction of disease outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!